Chronic aromatase inhibition, for example, with the drug letrozole, is used clinically in adjuvant therapy for estrogen receptor-positive breast cancer [in premenopausal women, aromatase inhibition must be combined with ovarian suppression; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2022]. This evidence concerns the gene CYP19A1 and breast carcinoma.